Here’s Why Novavax Stock Increased Today

Shares of Novavax (NVAX) were up by more than 10% as of this writing. This was due to a well-executed series of presentations that the company gave at the Communicable Diseases and Immunisation Conference 2022 in Sydney, Australia.

The company’s talks concluded began two days ago and ended today. They all related to vaccine hesitancy, safely co-administering combination coronavirus and influenza vaccines, as well as the efficacy of adjuvants. These were presented in the context of Novavax’s clinical data.

What Comes Next

Novavax states that the data referenced is not new to the general public.

Biotech stocks get their share prices upped when the company restates their most important results at a conference. Investors appear to have been simply paying attention to what Novavax brought to the table.

While the company is still waiting for the FDA to give its two cents on whether its coronavirus vaccine Nuvaxovid can be commercialized in the U.S. All they’re waiting for is the upcoming binding committee vote.

An approval from them would send Novavax’s shares to the stratosphere, but rejection could mean another stop for the company’s plans on selling in the U.S.

Investors shouldn’t worry, as the vaccine is approved in other various countries, so revenues are expected to continue to rise.

Buying the stock now might mean a great opportunity to increase your portfolio’s value if they do get approved.